Aims: The aim of this study was to evaluate the expression of transient receptor potential vanilloid type-1 chennel protein (TRPV1) in normal and tumor urothelial tissues; to correlate TRPV1 expression with clinico-pathological parameters and with disease-specific survival.
Methods and Results: TRPV1 expression was analyzed in normal and tumor urothelial samples at both mRNA and protein levels by Real-Time PCR and immunohistochemistry, respectively. TRPV1 down-regulation was found in UC specimens, which correlates with tumor progression. Moreover, TRPV1 mRNA levels were associated to clinico-pathological parameters to asses the role of TRPV1 down-regulation as a negative prognostic factor for survival. Kaplan-Meier survival analysis demonstrated a significantly shorter survival in patients showing TRPV1 mRNA down-regulation. Multivariate Cox regression analysis further indicated that TRPV1 mRNA expression retained its significance as an independent risk factor.
Conclusions:
The progression of UC of human bladder is associated with a marked decrease of TRPV1 expression, with a progressive loss in high-grade muscle invasive UC. Downregulation of TRPV1 mRNA expression may represent an independent negative prognostic factor for the survival probability of bladder cancer patients. 3 
Introduction
Cancer of the bladder is the fourth most frequent cancer among men in Europe 1 and the fifth most common cancer in United States. 2 More than 90% of bladder carcinomas are urothelial carcinoma derived from the urothelium, 6% to 8% are squamous cell carcinomas and 2% are adenocarcinomas. 3 About 70% of superficial (Ta and T1) tumors recur, and 10-20% are invasive. Of all diagnosed patients, up to 25% have muscle invasive tumors (pT2-pT4) at first presentation, but most patients (75-80%) present non invasive (pTa) and superficial invasive (pT1) tumors. 4, 5 Clinico-pathological markers such as stage, grade, size, multifocality of transitional cell carcinoma (TCC), presence of carcinoma in situ, lymph node status and the risk of recurrence or progression of bladder tumours are currently the most useful parameters for making therapeutic decisions and evaluating the follow-up and prognosis of patients with bladder cancer. However, due to tumour heterogeneity and differences in the biological behavior of urothelial cancers (UCs), classical prognostic factors do not accurately predict the clinical outcome of many patients with bladder cancer, and great efforts in searching new and more powerful molecular markers have been made. [6] [7] [8] Malignant cell transformation is often accompanied by changes in ion channel expression. 9 Over the past decade, an increasing set of data have revealed that changes in transient receptor potential (TRP) channel expression are associated with cancer development and metastasis. 10 TRPV1 is a non-selective cation channel structurally related to the members of TRP family of ion channels. It is activated by increased temperature with a threshold of about 43 °C at pH 7.4, and in addition to capsaicin (CPS), by lipoxygenase metabolites, endogenous endocannabinoids, and protons. 11 TRPV1 is mainly expressed by primary sensory neurons involved in nociception and neurogenic inflammation; however, it can be also present in non neuronal cells. 11, 12 In the F o r P e e r R e v i e w 4 urinary bladder, TRPV1 is expressed within afferent nerve terminals, basal and apical urothelial cells and interstitial cells. [13] [14] [15] [16] As in other cell systems, pain perception was the first role attributed to TRPV1 in the urinary tract; 17 in addition, a functional role of urothelial TRPV1 in normal bladder afferent mechanisms for perception of mechanical and irritant stimuli has been reported. 18, 19 Furthermore, an involvement of TRPV1 in cell differentiation has been recently suggested. 20 Many evidences suggest that TRPV1 contributes to growth and progression of several malignancies 21, 22 and increased TRPV1 expression has been found in prostate, colon, pancreas and bladder cancers. 20, 21, 23, 24 Moreover, we have previously shown that TRPV1 expression inversely correlates with glioma grade. 25
Little evidence concerning the expression and function of TRPV1 in human bladder cancer are available so far. In a cohort of 29 TCC patients, a loss of TRPV1 protein expression in the urothelium was observed, as TCC stage increases and cell differentiation decreases. 20 In addition, we have recently reported the expression of TRPV1 in human UC cell lines and the involvement of this channel receptor in the apoptosis induced by the selective agonist CPS. In this study we used bladder tissue samples from 62 adult patients undergoing transurethral resection of superficial UC (n=25) or radical cystectomy for muscle-invasive bladder cancer (n=37), enrolled between February 1999 and January 2007 at the Urology Operative Unit, ASUR 9, Macerata, Italy. All patients gave their consent, and a local ethics committee approved this study. All the specimens were embedded in paraffin, and 5-7 µm thick sections were collected on slides (n=8, for each specimen) and processed for immunohistochemistry.
CPS-induced apoptosis was associated with a rapid [Ca
Bladder tumours were histologically diagnosed according to the 1973 World Health Organization (WHO) classification system.
RNA EXTRACTION AND REVERSE TRANSCRIPTION
Total RNA from fixed paraffin-embedded tissue slices (5-7 µm thick) was isolated by Absolutly RNA ® FFPE kit (Stratagene, Austin, TX, USA) as previously described. 22 All RNA samples were eluted in the appropriate buffer and their concentration and purity were evaluated by A 260nm measurement. Five hundred nanograms of RNA extracted were subjected to reverse transcription in a total volume of 50 µl using the High-Capacity cDNA Archive Kit (PE Applied Biosystems, Foster City, CA) accordingly to the manufacturer's instructions.
Two µl of the resulting cDNA products were used as template for PCR quantification. 
HAEMATOXYLIN-EOSIN STAINING AND IMMUNOHISTOCHEMISTRY
Haematoxylin-eosin staining confirmed that all the specimens classified as NB (n=5) showed no dysplasia or carcinoma. Pathologic examination confirmed the presence of superficial UC in 25 patients and muscularis propria invasive UC in 37 patients. We evaluated TRPV1 mRNA expression in differently staged and graded UC specimens (Table 1) by qRT-PCR ( Figure 1 ). The mean value of TRPV1 expression in NB tissues was used as control. Starting from superficial pTa and pT1 towards the more invasive pT2, pT3 and pT4 stages, we observed a progressive down-regulation of TRPV1 mRNA expression, reaching very low levels in muscle-invasive pT3-pT4 (about 10 fold decrease with respect to normal tissue), (p< 0.0001; Figure 1A ). Moreover, a gradual decrease of TRPV1 mRNA expression was observed as grade increased, independently from the stage, with significant loss of receptor expression in G3 tissues as compared to NB (p< 0.001, Figure 1B ).
LOSS OF TRPV1 PROTEIN IN HIGH STAGED MUSCLE INVASIVE UC TISSUES
The results obtained by qRT-PCR in UC tissues prompted us to evaluate also the expression of TRPV1 protein by immunohistochemistry and semiquantitative analysis ( Figure 2 and Table 2 ). As previously reported, 18 NB was immunoreactive, with superficial cells showing a higher staining than basal and club-shaped cells (Figure 2b) ; the labeling was intracytoplasmatic and mainly distributed in granular structures. Consistent with qRT-PCR data, a marked decrease up to an absence of TRPV1 labeling was found in UC specimens of high grades and stages as differentiation levels decreased, with faintly staining observed only in more superficial cells, but not in muscle-invading cells (Figure 2f and 2g ). By contrast, in superficial UC specimens of cases staged as pTa, labeling intensity was similar or slightly lower than that observed in NB specimens. In the cases staged as pT1 and pT2 the labeling intensity was markedly reduced (Figure 2c and 2d) . No reactivity was found with normal rabbit serum used as negative control (Figure 2a ). Moreover, by semiquantitative analysis, no immunoreactivity was evidenced in pT3G3, pT4G3 stages and in the majority (75%) of pT3G2 samples; weak immunoreactivity in 55% of pT3 (G2 and G3) cases; moderate immunoreactivity in 50% of pT1 (G2 and G3) and pTaG2 specimens, respectively; moderate (67%) to strong immunoreactivity (33%) in pTaG1 tumours; and finally strong staining in all NB specimens (Table 2) . Finally, differently from data previously reported, 20 we found that TRPV1 mRNA and protein expression was maintained in more differentiated superficial pTaG1 and pT1G2 UC tissues.
TRPV1 EXPRESSION AND PATIENT SURVIVAL TIME (Table 3) . Similar results were obtained in a subgroup of patients without diagnosed metastasis (M0) ( Table 3 ; Figure 3 ). Thus, the reduced TRPV1 mRNA expression observed in UC patients strongly correlated with poor prognosis and short survival.
We additionally performed a stratified multivariate analysis based on Cox regression model, to test the influence of the selected parameters (TRPV1 mRNA expression and tumor grade) on the survival of all patients or in a pT2/T3/T4 subgroup (Table 4 ). We found that the degree of TRPV1 expression retained its significance as an independent prognostic factor in all groups of patients (P = 0.004) and in the pT2/T3/T4 subgroup (P = 0.030). Moreover, the analysis of TRPV1 mRNA expression levels in a more homogeneous group of patients 
Discussion
Changes in TRP channel expression are associated with cancer development and metastasis. It has also been suggested that some TRP channels may serve as prognostic or diagnostic markers. 10 Among the TRP superfamily, TRPV channels (TRPV1-6) are mainly involved in the regulation of growth and progression of genitourinary cancers. Thus, in prostate adenocarcinoma, TRPV1 and TRPV6 channels are overexpressed, with respect to healthy prostate tissues, and their expression levels strictly correlated with Gleason score, pathological stage, extraprostate extention and tumor grades. 22, 28, 29 Moreover, a role for TRPV6 in survival, proliferation and resistance to apoptosis of LNCaP prostate cancer cells via a Ca 2+ /NFAT dependent pathway 30 was reported together with a role of TRPV2 in the migration of prostate cancer cells in response to lysophospholipids. 31 In bladder cancer, a progressive loss of TRPV1 protein expression in the urothelium, as TCC stage increased and cell differentiation decreased, was previously described. 20 In addition, we recently demonstrated that stimulation of TRPV1 triggers the ATM/CHK2/p53 DNA damage response pathway and Fas/CD95-mediated intrinsic and extrinsic apoptotic pathways. 26 Moreover, we reported the overexpression of TRPV2 full-length and a parallel reduction of its short-splice variant s-TRPV2 in tumors of increasing grade and stage. These findings suggest the existence of a negative feedback mediated by s-TRPV2 that controls the expression of TRPV2 full-lenght in UCs. 32 In the present study, we found that TRPV1 is down-regulated in UC at both transcriptional and translational levels. Furthermore, more importantly, results from Kaplan-Meier analysis and Cox proportional hazards regression models suggest that reduced TRPV1 mRNA levels may be an independent prognostic marker for poor survival.
As previously reported, 14, 15, 20 progression rate, and invasiveness, respectively, the significant reduction of TRPV1 mRNA we found in pTaG2 vs pTaG1 and pT1G3 vs pT1G2 may be particularly important in the evaluation of the stratification risk of recurrence and tumor progression of invasive versus not invasive superficial UCs. 33 Altogether, our findings demonstrate an inverse correlation between TRPV1 (mRNA and protein) expression and the pathological stage and grade in UC tissues. This strongly suggests that TRPV1 expression is negatively associated with UC progression.
The question that now arises is what might be the patho-physiological relevance of TRPV1 expression to UC tumorigenesis. Our recent data indicate that triggering of TRPV1 on UC cells activates Fas-mediated intrinsic and extrinsic apoptotic pathways. 26 Thus, it is conceivable that the reduced expression of TRPV1 represents an evasion mechanism by which the UC cells could evade anti-proliferative and pro-apoptotic signals. In support of this hypothesis, intravesical instillation of curcumin, a vanilloid-like molecule, by selective binding to TRPV1, inhibits TCC cell implantation and growth in a murine superficial bladder tumor model. 34 To further address the potential prognostic value of this receptor, we correlated TRPV1 mRNA expression with the clinico-pathological parameters and patient's survival. By univariate analysis (Kaplan-Meier method), the cumulative survival curves for the canonic prognostic parameters such as tumor grade, lymph nodes and distant diagnosed metastasis Taking in account that patients with metastasis generally have poor prognosis 35 , we selected a group of patients with similar tumor grade and stage, without distant diagnosed metastasis (M0) and lymph node positivity (N0); we observed that TRPV1 could successfully differentiate survival as a valuable and independent molecular marker.
Similarly, TRPV1 expression was recently evaluated in hepatocellular carcinoma (HCC)
where it seems correlate to a better prognosis of patients suggesting that it could be potentially used as a prognostic indicator of HCC. 36 In conclusion our results suggest that TRPV1 represents a potential prognostic marker for patients with urothelial carcinoma of the bladder. As an independent prognostic factor for poor disease outcome, TRPV1 may be useful to improve appropriate selection of postoperative follow-up protocols for individual patients. Table 2 . Immunoreactivity of TRPV1 in normal bladder and urothelial carcinoma tissues at different pathologic stages.
NB = normal bladder
The extent and the intensity of TRPV1 staining were evaluated. 0 = immunonegativity; 1 = weak immunopositivity; 2 = moderate positivity; 3 = strong positivity. Relative risk (95% CI)
F o r P e e r R e v i e w
All patients (n = 62) pTa/T1 (n = 24) pT2/T3/T4 (n = 38) TRPV1 (Low/ Moderate/High) 0.26 (0.10-0.64) p = 0.004 0.61 (0.07-5.03) p = 0.651 0.30 (0.10-0.88) p = 0.030
Tumor grade (G1/G2/G3) 1.52 (0.74-3.12) p = 0. 
